Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, Pozzoni P, Giorgini A, Fabris P, Romano A, Lomonaco L, Puoti M, Vinci M, Gatti F, Carolo G, Zoncada A, Bonfanti P, Russo FP, Aghemo A, Soria A, Centenaro R, Maggiolo F, Rovere P, Pasin F, Paon V, Faggiano G, Vario A, Grossi G, Soffredini R, Carriero C, Paolucci S, Noventa F, Alberti A, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia and Veneto Study Groups.
Degasperi E, et al. Among authors: rossi mc.
J Hepatol. 2019 Dec;71(6):1106-1115. doi: 10.1016/j.jhep.2019.07.020. Epub 2019 Aug 6.
J Hepatol. 2019.
PMID: 31433303